Immunosuppressive regimens after a heart transplant can hamper good therapeutic progressions in fibrosis
The Yoshinori Yoshida laboratory reports the generation of a platform of human heart organoids derived from iPS cells, which they use to test new therapeutic alternatives on cardiac fibrosis. Their study is published in Frontiers ...
Nov 15, 2022
0
5